Show simple item record

dc.creatorKuo, Tsun-Yung
dc.creatorLin, Meei-Yun
dc.creatorCoffman, Robert L.
dc.creatorCampbell, John D.
dc.creatorTraquina, Paula
dc.creatorLin, Yi-Jiun
dc.creatorLiu, Luke Tzu-Chi
dc.creatorCheng, Jinyi
dc.creatorWu, Yu-Chi
dc.creatorWu, Chung-Chin
dc.creatorTang, Wei-Hsuan
dc.creatorHuang, Chung-Guei
dc.creatorTsao, Kuo-Chien
dc.creatorChen, Charles
dc.identifier.citationKuo, TY., Lin, MY., Coffman, R.L. et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep 10, 20085 (2020).
dc.description.abstractThe COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.
dc.format.extent10 pages
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartScientific Reports, Vol. 10
dc.relation.isreferencedbySpringer Science and Business Media LLC
dc.rightsAttribution CC BY
dc.titleDevelopment of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
dc.type.genreJournal article
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.temple.creatorChen, Charles

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY